Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK2256098

Known as: FAK Inhibitor GSK2256098, Focal Adhesion Kinase Inhibitor GSK2256098 
A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BackgroundCombined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2018
2018
Background GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in… Expand
Is this relevant?
2018
2018
409Background: MEK (mitogen-activated protein kinase kinase) is activated through mutated KRAS in > 90% of PDAC. Focal adhesion… Expand
Is this relevant?
2016
2016
BACKGROUND Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2015
2015
2593 Background: The focal adhesion kinase (FAK) and MAPK pathways share common upstream activators and contribute to cell… Expand
Is this relevant?
2015
2015
PTEN is known to be frequently mutated in uterine cancer and also dephosphorylates FAK. Here, we examined the impact of PTEN… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
BACKGROUND: Focal adhesion kinase (FAK) is overexpressed in glioblastoma (GBM) and is associated with poor prognosis. The FAK… Expand
Is this relevant?
2014
2014
Focal adhesion kinase (FAK) hyperactivation is common in pancreatic ductal adenocarcinoma (PDAC). A small molecule, GSK2256098… Expand
Is this relevant?
2012
2012
3000 Background: FAK has an important role in cancer invasion and metastasis. FAK and phospho-FAK (pFAK) are increased in… Expand
Is this relevant?
2012
2012
Results: Preliminary data are presented for 43 patients (25 M, 18 F), median age 64 years. No dose-limiting toxicities or serious… Expand
Is this relevant?